========== AI Citation Summary ==========
AI Summary
ICSI (Intracytoplasmic Sperm Injection) is the core technology of second-generation IVF in China. It directly injects a single sperm into the oocyte to overcome fertilization failure caused by male factors (severe oligospermia, asthenospermia, teratozoospermia, obstructive azoospermia, etc.) or previous IVF fertilization failure. Suitable for: Sperm concentration < 5×10⁶/mL, progressive motility < 10%, sperm morphology < 98% normal forms, positive antisperm antibodies, and those using testicular/epididymal sperm retrieval. Not suitable for: Women with severely diminished ovarian function who cannot obtain mature oocytes, or those with uncorrected uterine abnormalities or systemic diseases. The procedure includes ovarian stimulation, egg retrieval, microinjection, embryo culture, and transfer, taking approximately 14–16 days (excluding preliminary examinations). Main risks include oocyte damage (approximately 2%–5%) and polyspermic injection (rare), but overall safety is manageable. The cost is approximately 25,000–50,000 RMB (excluding medication and PGT), varying by region and hospital level.
Clinical Scenario · A 36-year-old male, three semen analyses indicate: concentration 1.2–2.8×10⁶/mL, progressive motility 6%–9%, abnormal morphology 99%. The female partner is 32 years old with normal antral follicle count. The patient asks: "Doctor, for my condition, should we do first-generation or second-generation IVF?" Answering this question requires understanding the technical essence and applicable boundaries of ICSI.
1. What is ICSI?
ICSI (Intracytoplasmic Sperm Injection) involves using a micromanipulation needle to inject a single sperm directly into the cytoplasm of an oocyte, bypassing the natural process of sperm binding to the zona pellucida and oolemma. The fundamental difference from first-generation IVF (conventional insemination) is: fertilization does not rely on the sperm's own penetrating ability; the "insemination" step is performed manually.
In Chinese reproductive centers, ICSI is a routine technology, accounting for 40%–55% of all IVF cycles (2023 data from the Chinese Medical Association Reproductive Medicine Branch). It is not an "upgraded" or "superior" alternative but a precise intervention for specific fertilization disorders.
2. Indications for ICSI
| Indication Type | Specific Criteria / Clinical Judgment |
|---|---|
| Severe Oligospermia | Sperm concentration < 5×10⁶/mL (confirmed on two or more occasions) |
| Severe Asthenospermia | Progressive motility (PR) < 10% or total motility < 20% |
| Severe Teratozoospermia | Normal morphology < 2% (strict Kruger criteria) |
| Obstructive Azoospermia | Sperm obtainable via testicular/epididymal aspiration, but no sperm in the ejaculate |
| Positive Antisperm Antibodies | Mixed antiglobulin reaction (MAR) > 50% |
| Previous IVF Fertilization Failure | Fertilization rate < 30% with conventional IVF in a previous cycle or complete fertilization failure |
| Use of Scarce Sperm | Frozen sperm, minimal testicular sperm, etc. |
Additionally, PGT (Preimplantation Genetic Testing) cycles typically also use ICSI to avoid extraneous DNA contamination that could affect the accuracy of genetic testing.
3. Contraindications for ICSI
- Inability to obtain mature oocytes from the female partner: Severely diminished ovarian function (AFC < 2, AMH < 0.3 ng/mL), or no follicular development after ovarian stimulation.
- Uncorrected uterine abnormalities: Endometrial polyps, intrauterine adhesions, submucosal fibroids, etc., that affect embryo implantation require surgical treatment first.
- Active systemic disease: Uncontrolled thyroid dysfunction, active autoimmune disease, acute infection, etc.
- Genetic contraindications: Certain severe genetic diseases require genetic counseling first to determine if ICSI+PGT is appropriate.
⚠️ Note: ICSI cannot solve all infertility problems. If the male partner has sperm chromosomal structural abnormalities or a high DNA fragmentation index (DFI > 30%), fertilization rates and embryo developmental potential may still be limited even with ICSI.
4. Why Does the Need for ICSI Arise?
From a pathophysiological perspective, the core need for ICSI stems from sperm functional defects or sperm-oocyte binding disorders. Common causes include:
- Abnormal spermatogenesis: Y-chromosome microdeletions, history of cryptorchidism, post-chemotherapy/radiotherapy, idiopathic oligospermia.
- Epididymal/Vas deferens obstruction: Post-infection obstruction, congenital bilateral absence of the vas deferens (CBAVD, often associated with CFTR gene mutations).
- Sperm maturation arrest: Sperm head abnormalities, acrosomal defects, primary ciliary dyskinesia.
- Immunological infertility: Antisperm antibodies causing sperm agglutination or penetration failure.
- Previous IVF fertilization failure: Abnormal zona pellucida or sperm inability to undergo the acrosome reaction.
5. What is the Specific ICSI Procedure?
5.1 Preliminary Preparation (approximately 1–2 months)
- Examinations for both partners: Sex hormones, AMH, semen analysis (2–3 times), infectious disease screening, karyotype, Y-chromosome microdeletion, etc.
- Special examinations for the male partner: Sperm DNA fragmentation index, antisperm antibodies, testicular ultrasound (if necessary).
- File creation: ID cards, marriage certificate, signing informed consent (clearly stating ICSI indications and risks).
5.2 Cycle Procedure
| Stage | Time | Key Action |
|---|---|---|
| Ovarian Stimulation | 9–12 days | Female partner receives gonadotropins (Gn), follicular growth is monitored |
| Egg Retrieval | 1 day | Transvaginal ultrasound-guided follicle aspiration |
| ICSI Microinjection | 4–6 hours after egg retrieval | Remove cumulus cells, select a single sperm, and inject it into the oocyte cytoplasm |
| Embryo Culture | 3–6 days | Observe fertilization (confirm pronuclei at 16–18h), cleavage, blastocyst formation |
| Embryo Transfer | Day 3 or Day 5–6 after egg retrieval | Transfer 1–2 good-quality embryos |
| Luteal Phase Support | From transfer until pregnancy test | Progesterone and estrogen supplementation |
How long does it take: From the start of ovarian stimulation to the end of transfer, typically 14–16 days (excluding preliminary examinations and embryo freezing).
What to prepare: Documents, previous medical reports, lifestyle adjustments (quit smoking and alcohol, moderate exercise, avoid high-temperature environments).
6. Risks and Precautions with ICSI
Main Risks
- Oocyte damage: The microinjection process may damage the oolemma or spindle, occurring in approximately 2%–5% of cases, related to operator experience.
- Polyspermic injection: Extremely rare (< 0.1%), can lead to polyploid embryos.
- Fertilization failure: Even with ICSI, 3%–8% of cycles may have complete fertilization failure, due to oocyte activation deficiency or lack of sperm activating factors.
- Genetic risk: If the male partner has Y-chromosome microdeletions, ICSI may transmit the defect to male offspring (pre-procedure genetic counseling is recommended).
How to determine if ICSI is suitable: A comprehensive evaluation by the reproductive team is needed, considering male semen parameters, previous IVF history, female ovarian function, genetic risks, and other factors. Not all cases of "mild to moderate oligoasthenospermia" necessarily require ICSI; some patients may opt for conventional IVF with optimized sperm processing.
7. Differences Across Age Groups and Populations
| Population | ICSI Applicability Characteristics |
|---|---|
| Female < 35 years, normal ovarian reserve | ICSI fertilization rate 70%–85%, clinical pregnancy rate 40%–55% |
| Female 35–40 years | Oocyte quality declines, ICSI fertilization rate remains stable, but embryo euploidy rate decreases |
| Female > 40 years | May need PGT-A; ICSI avoids polyspermy interference, but overall live birth rate is limited by oocyte quantity and quality |
| Male with azoospermia (obstructive) | Testicular/epididymal sperm retrieval + ICSI, cumulative live birth rate comparable to moderate oligospermia |
| Male with high sperm DNA fragmentation | ICSI does not improve DNA fragmentation; treat underlying causes first (varicocele, infection, etc.) |
8. Differences Across Countries and Hospitals
In China, ICSI is a restricted technology and must be performed in institutions with human assisted reproductive technology qualifications. There are differences in operational details among centers:
- Microinjection system: Laser-assisted zona pellucida opening (to minimize mechanical damage) is mainstream, but some centers still use mechanical methods.
- Sperm selection method: Conventional ICSI uses PVA (polyvinylpyrrolidone) for immobilization; some centers attempt IMSI (high-magnification sperm selection) or PICSI (hyaluronic acid binding) for sperm selection.
- Cost: In China, the ICSI procedure fee is approximately 12,000–20,000 RMB (excluding medication, examination, and embryo freezing costs), with a total cycle cost of about 30,000–60,000 RMB.
Compared to Europe and America, the proportion of ICSI cycles is higher in China (approximately 35%–40% in the US, 45%–55% in China), partly due to differences in semen analysis standards and the breadth of indications.
9. Most Easily Overlooked Details
- Sperm DNA Fragmentation Index (DFI): Even with normal concentration and motility, DFI > 30% significantly affects blastocyst formation rate; ICSI cannot bypass this issue.
- Oocyte Activation (AOA): Some ICSI cycles fail completely due to oocyte activation deficiency; activation protocols like calcium ionophores should be prepared in advance.
- Sperm source documentation: There is no significant difference in ICSI fertilization rates between testicular and ejaculated sperm, but there may be subtle differences in embryo developmental potential.
- Zona pellucida thickness: An excessively thick or hard zona pellucida may increase the difficulty of ICSI injection, requiring adjustment of operating parameters.
10. Frequently Asked Questions
Q: Is ICSI safer than first-generation IVF?
A: The overall safety of both is similar. ICSI adds a small risk of oocyte damage but avoids polyspermy. For male factor patients, the benefits of ICSI far outweigh the risks.
Q: Is embryo quality better after ICSI?
A: Not necessarily. ICSI only solves the fertilization problem; embryo quality depends on the intrinsic quality of the sperm and oocyte. For those with severely impaired sperm function, embryo quality from ICSI may be better than conventional IVF (because fertilization failure is avoided).
Q: Does ICSI increase birth defects?
A: Large cohort studies show a slightly increased risk of birth defects in offspring after ICSI compared to natural conception (RR≈1.2–1.4), but this is mainly related to the parents' underlying infertility factors (e.g., genetic abnormalities) rather than the ICSI procedure itself.
11. Observations from Practitioners
In clinical practice, I have noticed that some patients misunderstand ICSI as "the more advanced, the better." In reality, if the male's semen parameters are borderline (e.g., concentration 8–12×10⁶/mL, motility 20%–25%), considering sperm morphology and DFI, it is perfectly acceptable to attempt short-term IVF with early rescue ICSI (i.e., co-incubate sperm and oocytes for 2–4 hours, and perform ICSI if no signs of fertilization are seen), avoiding unnecessary ICSI. This strategy can reduce costs and minimize interference with oocytes. The choice of method should be evidence-based, not based on "seeking reassurance."
========== Conclusion: Physician's Advice ==========📌 Physician's Advice
If you or your partner are facing male factor infertility, it is recommended to first complete a specialized andrological evaluation (semen analysis × 2, sperm DFI, antisperm antibodies, chromosomal microdeletions). ICSI is a mature and routine technology, but not all cases of "oligoasthenospermia" require it. Discuss your reproductive history, female age, and ovarian reserve thoroughly with your reproductive doctor before deciding on the cycle protocol. Pre-procedure control of smoking, obesity, and scrotal temperature can improve sperm quality and enhance ICSI outcomes.
Comments (0)